Cancer gene therapy using adeno-associated virus vectors

Area of Science:

• Oncology
• Gene Therapy
• Virology

Background:

• Gene therapy offers potential cancer treatments by introducing therapeutic genes to inhibit tumor growth and stimulate immune responses.
• Viral and non-viral gene delivery systems are crucial for effective cancer gene therapy.
• Adeno-associated virus (AAV) vectors are highly regarded for gene therapy due to their safety, broad infectivity, and low immunogenicity.

Purpose of the Study:

• To review the basic biology of adeno-associated virus (AAV).
• To focus on recent advancements in AAV vector development for cancer gene therapy.
• To highlight AAV-mediated therapeutic strategies against cancer.

Main Methods:

• Literature review of adeno-associated virus (AAV) biology and vector development.
• Analysis of AAV's properties relevant to cancer gene therapy.
• Summary of recent progress in AAV-mediated cancer treatment strategies.

Main Results:

• AAV vectors possess key features like non-pathogenicity, ability to infect various cell types, and low immune response, making them suitable for gene therapy.
• AAV vectors demonstrate a strong safety profile in clinical trials for various diseases.
• Despite frequent use of other oncolytic viruses, AAV holds significant potential for cancer gene delivery.

Conclusions:

• Adeno-associated virus (AAV) vectors are a promising platform for developing novel cancer gene therapies.
• Further research into AAV vector development can enhance its application in oncology.
• AAV-mediated gene therapy represents a viable strategy for cancer treatment with a favorable safety profile.